BostonGene Named
2026 Global Company of the Year

BostonGene has been recognized as Frost & Sullivan’s 2026 Global Company of the Year in AI-Driven Multimodal Oncology Platforms.

Discover how our biologically grounded foundation models are setting the new standard for de-risking drug development and optimizing clinical trial design.

Refine biomarker strategies using simultaneous tumor and immune profiling.
Improve decision-making by assessing therapy response before trial design.
Accelerate development with CLIA-certified, regulatory-grade AI insights.

Get the Full Report

Access the Frost & Sullivan comprehensive analysis and benchmarking report.

First Name

Last Name

Phone number

Work Email

Job title

Company name

Yes, I would like to receive marketing communications regarding BostonGene products, services, and events. I may unsubscribe at any time.

You agree to our privacy policy You agree to our privacy policy.

Thanks For Your Interest!

A copy of the file has also been sent to your email address.

Availability

Our friendly team is here to help.

Mon – Fri, 9:00 AM – 5:00PM

Call toll-free

Questions or queries? Get in touch!

(781) 552-3131

Email

You can email us at

[email protected]